← All trials
NCT05786547
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2023
- Primary completion
- Jul 20, 2025
- Completion date
- Jul 20, 2025
- First posted
- Mar 27, 2023
- Last posted
- Dec 6, 2023
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Colorado, DenverLead sponsor
- National Cancer Institute (NCI)Collaborator
- Harvard UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.